Table 2.
The effect of bezafibrate and omega-3 fatty acids on the lipid profile and glucose homeostasis markers in hypertriglycericemic patientsa
| Assay results | Treatment groups | ||
|---|---|---|---|
| Placebo | Omega-3 fatty acids | Bezafibrate | |
| Total cholesterol (mg/dL) | |||
| Baseline | 168.9 ± 7.3 | 170.2 ± 8.1 | 169.8 ± 8.0 |
| Before randomization | 166.1 ± 6.7 | 169.2 ± 4.9 | 168.3 ± 4.9 |
| After 4 weeks of treatment | 164.4 ± 6.9 | 173.6 ± 6.8 | 142.5 ± 5.2#*^ |
| After 12 weeks of treatment | 168.5 ± 8.7 | 174.4 ± 6.8 | 142.1 ± 5.1#*^ |
| LDL-cholesterol (mg/dL) | |||
| Baseline | 101.3 ± 4.1 | 100.9 ± 6.0 | 102.3 ± 3.7 |
| Before randomization | 100.3 ± 4.2 | 99.5 ± 5.7 | 102.1 ± 3.5 |
| After 4 weeks of treatment | 99.8 ± 3.9 | 102.3 ± 4.6 | 88.7 ± 4.8#*^ |
| After 12 weeks of treatment | 102.5 ± 4.2 | 104.2 ± 5.0 | 87.5 ± 5.0#*^ |
| HDL-cholesterol (mg/dL) | |||
| Baseline | 37.7 ± 1.2 | 37.1 ± 1.5 | 37.3 ± 1.4 |
| Before randomization | 37.5 ± 1.9 | 38.2 ± 1.4 | 37.5 ± 1.5 |
| After 4 weeks of treatment | 38.0 ± 1.5 | 39.3 ± 1.7 | 45.2 ± 1.7##*^ |
| After 12 weeks of treatment | 37.8 ± 1.4 | 39.7 ± 2.0 | 46.1 ± 1.6##**^ |
| Triglycerides (mg/dL) | |||
| Baseline | 380.2 ± 36.4 | 378.2 ± 39.2 | 371.2 ± 35.1 |
| Before randomization | 366.2 ± 30.3 | 348.8 ± 38.1 | 351.2 ± 31.8 |
| After 4 weeks of treatment | 346.5 ± 43.2 | 268.1 ± 28.0# | 225.3 ± 27.2###*** |
| After 12 weeks of treatment | 344.1 ± 46.5 | 240.1 ± 29.7##** | 218.2 ± 28.3###*** |
| Fasting glucose (mg/dL) | |||
| Baseline | 96.0 ± 2.9 | 95.9 ± 2.6 | 96.4 ± 2.4 |
| Before randomization | 94.9 ± 3.5 | 94.6 ± 3.1 | 96.0 ± 3.2 |
| After 4 weeks of treatment | 96.5 ± 3.0 | 94.0 ± 2.9 | 92.4 ± 2.9 |
| After 12 weeks of treatment | 95.1 ± 2.8 | 95.1 ± 3.7 | 91.8 ± 3.5 |
| 2-h post-glucose load plasma glucose (mg/dL) | |||
| Baseline | 137.0 ± 8.7 | 136.9 ± 5.8 | 138.0 ± 6.2 |
| Before randomization | 138.2 ± 8.0 | 131.1 ± 7.0 | 137.2 ± 5.3 |
| After 4 weeks of treatment | 138.8 ± 8.3 | 137.9 ± 6.8 | 125.1 ± 4.9 |
| After 12 weeks of treatment | 136.5 ± 7.5 | 140.9 ± 6.5 | 123.2 ± 5.5^ |
| HOMA | |||
| Baseline | 3.7 ± 0.2 | 3.5 ± 0.4 | 3.8 ± 0.5 |
| Before randomization | 3.6 ± 0.4 | 3.4 ± 0.3 | 3.8 ± 0.4 |
| After 4 weeks of treatment | 3.4 ± 0.3 | 3.7 ± 0.4 | 3.0 ± 0.3#^ |
| After 12 weeks of treatment | 3.5 ± 0.3 | 3.8 ± 0.3 | 1.9 ± 0.2###***^^^$$ |
Significance levels: # p < 0.05, ## p < 0.01, ### p < 0.001 vs. respective value before randomization. *p < 0.05, **p < 0.01, ***p < 0.001 vs. placebo-treated patients. ^p < 0.05, ^^^p < 0.001 vs. omega-3 fatty acid-treated patients. $$ p < 0.01 vs. respective value after 4 weeks of treatment
Data are given as the mean±SD.
aOnly data of patients who completed the study were included in the final analyses